Clinical Trial Details


Research Study Summary

A randomized, placebo-controlled, double-blind study of Ly2216684 flexible dose 12 mg to 18 mg once daily and LY2216684 fixed dose 6 mg once daily as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.


The primary objective of this study is to assess whether LY2216684 (12 mg to 18 mg flexible dose QD) is better than placebo to increase the effectiveness of a patient's current medication treatment for major depressive disorder when taken once daily in addition to a patient's current stable major depression treatment.

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID: 176872
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Both Male and Female
Overall Status
Facility Type


Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information:

Alexian Brothers Hospital Network

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.